BioVersys reports Phase 2a ENABLE results showing dose-dependent bactericidal activity for alpibectir plus ethionamide in pulmonary tuberculosis.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
BioVersys AG reported positive early bactericidal activity (EBA) findings from its completed 14-day Phase 2a ENABLE study evaluating alpibectir combined with ethionamide (AlpE) in patients with newly diagnosed, drug-sensitive pulmonary tuberculosis (TB). The higher-dose AlpE regimen combined with rifampicin, pyrazinamide and ethambutol (RZE) demonstrated bactericidal activity numerically similar to standard-of-care HRZE, supporting further evaluation of the investigational combination as a potential alternative to isoniazid-containing treatment.
Alpibectir-Ethionamide Combination Targets Improved Antituberculosis Activity
AlpE combines alpibectir, an investigational antibacterial agent, with ethionamide, an established antituberculosis drug. Alpibectir potentiates the activity of ethionamide and its active metabolite, providing the scientific rationale for evaluating the combination in multidrug treatment regimens.
The development programme is progressing through a collaboration involving BioVersys and GSK, with potential applications in pulmonary TB and TB meningitis. The combination is particularly relevant to efforts to develop alternative treatment options for patients who cannot benefit from conventional isoniazid-containing regimens.
Phase 2a ENABLE Study Shows Dose-Dependent Bactericidal Activity
The Phase 2a ENABLE study (NCT06748937) evaluated alpibectir at 45 mg, a higher dose than previously investigated, combined with either 125 mg or 250 mg of ethionamide.
Researchers assessed AlpE both as a standalone combination and alongside RZE. In the combination regimen, AlpE replaced isoniazid in the standard four-drug HRZE regimen, which comprises isoniazid, rifampicin, pyrazinamide and ethambutol.
All evaluated regimens demonstrated bactericidal activity over the 14-day treatment period. However, the magnitude of early bactericidal activity depended on the ethionamide dose, with the 250 mg regimen showing greater activity than the 125 mg regimen.
Importantly, AlpE at 45 mg/250 mg combined with RZE produced EBA results numerically similar to standard-of-care HRZE. The investigators cautioned that the study was not designed for formal statistical comparisons between treatment arms. Therefore, the findings establish an encouraging early clinical signal rather than demonstrating therapeutic equivalence or superiority.
AlpE was generally well tolerated, with an acceptable safety profile during the 14-day evaluation.
Clinical Development Extends to Phase 2b Pulmonary TB Trial
The findings were presented at the Union World Conference on Lung Health, held from November 17 to 20, 2026, in Rio de Janeiro, Brazil. Conference presentations covered ENABLE efficacy, safety and pharmacokinetic findings, alongside additional clinical microbiology data examining alpibectir’s contribution to ethionamide activity.
The next stage of pulmonary TB development includes the ongoing Phase 2b STEP2C trial (NCT05807399), which is evaluating AlpE-RZE during the first two months of treatment. The study began enrolling patients following its first-patient-first-visit milestone in March 2026 and is being conducted across six African countries.
The trial operates under the European Union’s Innovative Medicines Initiative 2 (IMI2) UNITE4TB programme, with the Institute of Infectious Diseases and Tropical Medicine at LMU University Hospital Munich serving as sponsor.
Separately, BioVersys is advancing another Phase 2 programme evaluating alpibectir-containing regimens in TB meningitis.
Further Clinical Evidence Needed to Establish Therapeutic Potential
GSK’s Head of Global Health Medicines R&D, Dr. David Barros-Aguirre, highlighted the findings as additional clinical evidence supporting continued evaluation of AlpE in future TB treatment regimens.
BioVersys CEO Dr. Marc Gitzinger also emphasised the importance of the collaboration with GSK and the academic and public-sector partners involved in advancing the programme.
The ENABLE results provide an early clinical signal that higher-dose ethionamide combined with alpibectir can deliver bactericidal activity within a multidrug regimen. However, the ongoing Phase 2b programme will be important in determining whether this activity translates into meaningful treatment outcomes over longer treatment periods.
Reference
BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE, Bioversys, 20 November 2026
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination with Ethionamide (ENABLE), ClinicalTrials.gov ID NCT06748937
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.
